Adagene Inc. (ADAG) — SEC Filings

Latest SEC filings for Adagene Inc. (ADAG), explained in plain English.

Sentiment Overview: 3 bullish, 17 neutral

Recent Filings (20)

• 6-K Filing — 6-K · 2026-04-01T17:16:24-04:00 [neutral]
• Adagene Files 2025 Annual 20-F Report with SEC — 20-F · 2026-04-01T17:15:29-04:00 [neutral] Risk: high
  Adagene Inc. submitted its annual report on Form 20-F for the fiscal year ended December 31, 2025, to the SEC on April 1, 2026. This filing, required for foreig
• 6-K Filing — 6-K · 2025-11-13T00:00:00.000Z [neutral]
• Adagene Inc. Files 6-K with Q2 2025 Financial Updates — 6-K · 2025-08-12T00:00:00.000Z [neutral] Risk: low
  Adagene Inc. filed a 6-K report on August 12, 2025, detailing its financial position as of June 30, 2025. The filing includes balance sheet information for the
• Adagene Inc. Files 6-K for Regulatory Update — 6-K · 2025-07-15T00:00:00.000Z [neutral] Risk: medium
  Adagene Inc. filed a Form 6-K on July 15, 2025, to report a regulatory update on its clinical development. The filing includes a press release detailing this up
• Sanofi Invests Up To $25M in Adagene — 6-K · 2025-07-01T00:00:00.000Z [bullish] Risk: medium
  On July 1, 2025, Adagene Inc. announced a strategic investment and option exercise by Sanofi. Sanofi Foreign Participations B.V. has agreed to invest up to US$2
• Adagene Reports Updated Phase 1b/2 Study Data — 6-K · 2025-05-22T00:00:00.000Z [neutral] Risk: medium
  Adagene Inc. filed a Form 6-K on May 22, 2025, to report updated data from its Phase 1b/2 study of Muzast. The press release, Exhibit 99.1, details these findin
• Adagene Inc. Files 6-K for FY 2024 Results — 6-K · 2025-03-24T00:00:00.000Z [neutral] Risk: low
  Adagene Inc. filed a Form 6-K on March 24, 2025, reporting its full-year 2024 financial results and providing a business update. The filing includes a press rel
• Adagene Inc. Files 2024 Annual Report — 20-F · 2025-03-24T00:00:00.000Z [neutral] Risk: medium
  Adagene Inc. filed its annual report on Form 20-F for the fiscal year ending December 31, 2024. The company, incorporated in E9 and headquartered in Suzhou Indu
• Adagene Inc. Reports Phase 1b/2 Study Data Update — 6-K · 2025-01-27T00:00:00.000Z [neutral] Risk: medium
  Adagene Inc. filed a Form 6-K on January 27, 2025, reporting updated data from its Phase 1b/2 study. The filing includes a press release titled "Adagene Announc
• SC 13G/A Filing — SC 13G/A · 2024-11-07T00:00:00.000Z [neutral]
• Adagene Inc. Files 6-K, Presents New Research Insights — 6-K · 2024-11-07T00:00:00.000Z [neutral] Risk: low
  Adagene Inc. filed a Form 6-K on November 7, 2024, reporting on its activities for the month of November 2024. The filing includes a press release titled "Adage
• Adagene Presents at ESMO Congress in September 2024 — 6-K · 2024-09-16T00:00:00.000Z [neutral] Risk: low
  Adagene Inc. filed a Form 6-K on September 16, 2024, to report its activities for the month of September 2024. The filing includes a press release titled "Adage
• Adagene Inc. Files 6-K with Mid-Year Financial Updates — 6-K · 2024-07-25T00:00:00.000Z [neutral] Risk: low
  Adagene Inc. filed a 6-K report for the period ending June 30, 2024. The filing includes financial data for the first six months of 2024 and the comparable peri
• Adagene Inc. Enters $100M Sales Agreement with Leerink Partners — 6-K · 2024-03-29T00:00:00.000Z [neutral] Risk: medium
  On March 29, 2024, Adagene Inc. entered into a sales agreement with Leerink Partners LLC. This agreement allows Adagene to potentially sell up to $100 million o
• Peter Luo Amends Adagene Inc. Ownership Filing — SC 13D/A · 2024-03-01T00:00:00.000Z [neutral] Risk: medium
  On March 1, 2024, Peter Luo filed an amendment (Amendment No. 2) to Schedule 13D for Adagene Inc. This filing indicates a change in beneficial ownership of Adag
• Adagene Expands ADG126/KEYTRUDA Colorectal Cancer Trial; Data Due 2024 — 6-K · 2024-02-09T00:00:00.000Z [bullish] Risk: medium
  Adagene Inc. announced on February 9, 2024, the expansion of its clinical collaboration for ADG126 (muzastotug), a masked anti-CTLA-4 SAFEbody, in combination w
• FMR LLC & Abigail Johnson Hold 6.414% Stake in Adagene Inc. — SC 13G/A · 2024-02-09T00:00:00.000Z [neutral] Risk: low
  FMR LLC, a major investment firm, and its principal owner, Abigail P. Johnson, have updated their ownership stake in Adagene Inc. (a pharmaceutical company) to
• Huang James, 03 Life Sciences Disclose Significant Adagene Stake — SC 13G · 2024-01-19T00:00:00.000Z [neutral]
  On January 18, 2024, Huang James, associated with 03 Life Sciences, filed an SC 13G indicating a significant ownership stake in Adagene Inc. (NASDAQ: ADAG). Thi
• Adagene's ADG126 Shows Clinical Benefit in Colorectal Cancer Trial — 6-K · 2024-01-16T00:00:00.000Z [bullish]
  Adagene Inc. filed a 6-K on January 16, 2024, announcing interim results for its masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in combination with Pembrolizu